Opinion|Videos|January 21, 2025
Cost-Effectiveness and Patient Support in Treating BCG-Unresponsive NMIBC
Author(s)Max Kates, MD
Max Kates, MD, discusses how newer therapies for BCG-unresponsive NMIBC may have better long-term cost-effectiveness despite higher initial costs, emphasizing the importance of leveraging patient assistance programs, copay cards, and foundation support to ensure treatment access while using cost comparison tools to help patients make informed decisions.
Advertisement
Episodes in this series
- Annual cost analyses suggest that some newer therapies may have higher up-front costs but can be more economical in the long run due to fewer recurrences and less frequent administration.
- How does the cost-effectiveness of treatments, particularly in relation to newer therapies, influence your recommendations for patients with BCG-unresponsive NMIBC?
- Are there specific tools or resources you rely on to help assess and present these options to patients?
- What financial assistance or patient support programs (eg, copay cards, patient assistance foundations, or programs) have you found most helpful in ensuring that patients can afford and access the right treatments, and how do you guide patients in utilizing these resources?
Advertisement
Related to this article
Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.
Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.
Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.
These FAQs outline key recommendations and practical takeaways from the AUA/SUFU/AUGS Genitourinary Syndrome of Menopause guideline.
Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.
Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.
This approval expands the label for nogapendekin alfa inbakicept to include patients with high-grade papillary-only tumors.
Melissa Hadley Barrett discusses real-world outcomes and tolerability of intranasal vardenafil for men with persistent erectile dysfunction despite prior standard therapy.
Advertisement
Advertisement
Trending on Urology Times
1
Anktiva plus BCG shows durable responses in BCG-unresponsive NMIBC
2
Sandip Prasad, MD, on the safety profile of mitomycin intravesical solution
3
Three-year data show durable responses with mitomycin intravesical solution
4
FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC
5